N/A N=45 Monitoring of Symptoms and Cognitive Function Using Telehealth
End Stage Liver Disease
Primary: Patient Satisfaction — 45 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=17 A Physical Activity Program in End-state Liver Disease
End-stage Liver Disease (ESLD) · Liver Transplant · Sarcopenia
Primary: Physical Fitness - VO2 — -1; -3 mL oxygen/kg/min — p=0.49
N/A N=1,494 Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD)
End Stage Liver Disease · Decompensated Cirrhosis of Liver
Primary: Quality of Life (QOL) — 7.02; 8.01 score on a scale
Phase 3 N=203 Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure
Acute Alcoholic Hepatitis
Primary: Overall Survival — 57; 66 Participants — p=0.904
N/A N=2,600 Chinese CLIF-C Acute-on-Chronic Liver Disease and Liver Failure Study
Liver Failure, Acute on Chronic
Primary: 28-day Mortality,28-day Liver-transplantation Free Mortality& 28-day Liver Transplantation Rate — 74; 124; 74 Participants
N/A N=50 A Randomized Controlled Trial of an Advanced Care Planning Video Decision Support Tool for Patients With End-Stage Liver Disease
End Stage Liver Disease
Primary: Number of Eligible Participants Enrolled in the Study — 50 Participants
Phase 2 N=2 LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
Phase 2 N=5 A Phase I/II Safety and Tolerability Dose Escalation Study of Autologous Stem Cells to Patients With Liver Insufficiency
Liver Disease
Primary: Number of Patients Who Tolerated the Maximum Dose — 5 Participants
N/A N=63 A Study to Evaluate Liver Stiffness With Shear Wave Elastography
Chronic Liver Disease · Advanced Fibrosis · Advanced Cirrhosis
Primary: Median Endoscopic Ultrasound (EUS) Shear Wave Elastography — 0.11 kPA
Phase 2 N=95 Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 93.3; 100.0; 84.2 percentage of participants
N/A N=5 Adult Stem Cell Therapy in Liver Insufficiency
Liver Cirrhosis
Primary: Number of Participants With Serious Adverse Events Related to Injection — 0 Participants
Phase 3 N=81 HELPS Study - A Study of Peginterferon Alfa-2a (Pegasys) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease (ESRD)
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virological Response (SVR) at 24 Weeks After End of Treatment — 39.5; 34.9 percentage of participants — p=0.6746
Phase 4 N=312 Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection
End Stage Liver Disease · Hepatitis C
Primary: Freedom From Acute Rejection or HCV Recurrence or Treatment Failure — 69; 70; 133 participants
N/A N=180 Sonoelastography: Ultrasound Method to Measure Liver Fibrosis
Chronic Liver Disease · Non-Alcoholic Fatty Liver Disease · Hepatitis C Virus (HCV) Coinfection
Primary: Liver Elasticity Value Measured Using Sonoelastography (SE) — 7.225; 7.332; 8.548; 12.101 kilopascals (kPa)
N/A N=14 Team Science (The Liver Health Study)
Steatotic Liver Disease of Mixed Origin (MetALD)
Primary: Proportion Screened With Alcohol Intake and Weight-related Risks for Metabolism and Alcohol-associated Liver Disease — 26 Participants
N/A N=21 Endoscopic Ultrasound(EUS)-Guided TRUCUT Biopsy (EUS-TCB) of Suspected Nonalcoholic Fatty Liver Disease(NAFLD.)
Non-alcoholic Fatty Liver Disease · Nonalcoholic Steatohepatitis
Primary: Median Total Specimen Length — 8; 14; 8; 11.5 mm
Phase 1 N=119 HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis
End Stage Renal Disease on Hemodialysis (Diagnosis)
Primary: Percentage of Subjects Reporting Clinically Significant Adverse Events - Medically-attended Adverse Events, Serious Adverse Events, and Immune-mediated Adverse Events of…
N/A N=45 Using Ultrasound Elastography to Predict Development of SOS
Sinusoidal Obstruction Syndrome · Complications of Bone Marrow Transplant
Primary: Sensitivity and Specificity of US for VOD/SOS — 80; 93 percentage of participants
N/A N=50 HRQoL in the Low MELD Pre-tx Population
Cirrhosis of the Liver
Primary: Perceived HRQoL Score. Overall Qualty of Life Index Tool Was Utilized. — 20.19 scores on a scale
N/A N=70 Velacur by Sonic Incytes for Portal Hypertension
Portal Hypertension · Chronic Advanced Liver Disease
Primary: Liver Stiffness Measurements for Participants With Compensated Advanced Chronic Liver Disease With and Without Esophageal Varices Upon Esophagogastroduodenoscopy (EGD)…
Phase 3 N=66 Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase Deficiency
Lysosomal Acid Lipase Deficiency
Primary: Percentage Of Participants Achieving Alanine Aminotransferase Normalization — 31; 7; 56; 37 percentage of participants — p=0.0271
N/A N=28 Chronic Liver Disease in Urea Cycle Disorders
Urea Cycle Disorder
Primary: Liver Stiffness as Measured by Shear Wave Elastography — 13; 14 Participants
N/A N=130 Elastography of the Liver in Cystic Fibrosis Patients. Diagnostic and Prognostic Aspects
Cystic Fibrosis · Liver Fibrosis
Primary: Elastographic Value in kPa Measured by Fibroscan — 4.7 kPa
N/A N=30 Beyond Confounders: Addressing Source of Measurement Variability and Error in Shear Wave Elastography
Liver Fibrosis · Liver Diseases
Primary: Deviations From Suggested Guidelines- Any Effect on Agreement — 0.77; 0.75; 0.69; 0.86 correlation coefficient
Phase 3 N=410 Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites
Decompensated Cirrhosis and Ascites
Primary: Time to Liver Transplantation or Death Through 1 Year After Randomization: Percentage of Participants With an Event — 33.5; 38.6 percentage of participants — p=0.17
Phase 2 N=86 A Study of IDN-6556 in Subjects With Liver Cirrhosis
Liver Cirrhosis · Hepatic Cirrhosis
Primary: Change From Baseline at Month 3 in cCK18/M30 — 293.5; 257.5; 288.5; 285.0 U/L
Phase 2 N=9 The Sleep, Liver Evaluation and Effective Pressure Study
Non Alcoholic Fatty Liver Disease · Obstructive Sleep Apnea
Primary: Cross Sectional Analysis of NAFLD Versus Sleep Apnea Severity Indices (AHI)
Phase 3 N=95 Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients?
Adrenal Insufficiency · Cirrhosis · Spur Cell Anemia
Primary: Number of Participants With Cholesterol Esterification Deficiency — 10; 11 Participants
Phase 2 N=60 FMT in Cirrhosis and Hepatic Encephalopathy
Cirrhosis · Hepatic Encephalopathy
Primary: Serious Adverse Events Related to FMT — 0; 0; 0; 0 Participants
N/A N=21 EUS Guided Core Liver Biopsy and IGB Placement for the Diagnosis and Management of NASH and Obesity
Obesity · Non-Alcoholic Steatohepatitis
Primary: Weight Loss Achieved With Intragastric Balloon (IGB) — 17 Participants